Stress and Congestive Heart Failure
Launched by YALE UNIVERSITY · Sep 9, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how sudden stress might affect people who have congestive heart failure (CHF). The researchers want to understand if experiencing stress can make CHF symptoms worse for patients who already have the condition. The study is currently recruiting participants aged 18 and older who have a specific heart monitor called a Cardiomems implanted to help track their heart health.
To join the study, participants must have heart failure and be able to complete certain assessments. However, individuals with severe heart failure (Class IV), those with other serious medical conditions, or anyone unable to participate due to cognitive or physical disabilities will not be eligible. Participants will be monitored and asked to report their experiences during the study. This research could help improve understanding of how stress impacts heart health and lead to better care for people with CHF.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Heart failure patients over 18 who have or will be receiving a Cardiomems implanted PAP monitor.
- Exclusion Criteria:
- • Patients who are unable to perform EMA or laboratory assessments due to cognitive, visual, language, or other disabilities will be excluded.
- • Patients with Class IV heart failure will also be excluded, as they are already maximally decompensated, and a ceiling/floor effect would preclude effects of stress.
- • Patients with conditions other than heart failure that affect PA pressures (e.g. dialysis).
- • Patients with physical conditions that interfere with study participation.
- • Patients non-compliant with their PAP monitoring.
- • Patients with chronic opioid use will be excluded.
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Hartford, Connecticut, United States
Hartford, Connecticut, United States
Patients applied
Trial Officials
Rachel Lampert, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials